{"id":16531,"date":"2020-06-30T10:30:11","date_gmt":"2020-06-30T15:30:11","guid":{"rendered":"http:\/\/www.paristn.net\/articles\/?p=16531"},"modified":"2020-06-30T09:36:00","modified_gmt":"2020-06-30T14:36:00","slug":"fda-coronavirus-covid-19-update-june-28th-2020","status":"publish","type":"post","link":"https:\/\/www.paristn.net\/articles\/2020\/06\/30\/fda-coronavirus-covid-19-update-june-28th-2020\/","title":{"rendered":"FDA Coronavirus (COVID-19) Update: June 28th, 2020"},"content":{"rendered":"

\"U.S.Silver Spring, MD<\/strong> – <\/span>The U.S. Food and Drug Administration (FDA) today continued to take action in the ongoing response to the COVID-19 Coronavirus pandemic:<\/p>\n

The FDA and the Federal Trade Commission (FTC) jointly issued a warning letter<\/a> to Hong Kong<\/span>-based SuperHealthGuard and Loyal Great International, Ltd., advising these companies to cease selling unapproved products online to customers in the United States<\/span> with misleading claims that such products mitigate, prevent, treat, diagnose, or cure COVID-19 Coronavirus in people.<\/p>\n

\"Coronavirus.\"<\/a>

Coronavirus.<\/p><\/div>\n

<\/p>\n

The FDA’s action is in support of its efforts to protect the public health. FTC’s action enforces provisions of the FTC Act, 15 U.S.C. 41, prohibiting unsupported drug advertising claims. There are no drugs approved by the FDA to prevent or cure COVID-19 Coronavirus in people.<\/p>\n

FDA advised the companies to review their respective websites to ensure that they are not misleadingly representing unproven products as safe and effective for a COVID-19-related use. Failure to immediately correct the unapproved new drug and misbranding violations could result in legal action, including, without limitation, seizure and injunction.<\/p>\n

FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\/or effective for the treatment or prevention of COVID-19 Coronavirus.<\/p>\n

Misbranded or unapproved new drugs are subject to detention and refusal of admission, if they are offered for importation into the United States<\/span>. The list of firms that have received warning letters is located here<\/a>.<\/p>\n

FDA issued Emergency Use Authorizations (EUAs) for the following SARS-CoV-2 molecular diagnostic tests:<\/p>\n